TGFß SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE

Patent metadata

Field	Value
Publication number	US-2017191038-A1
Application number	US-201515326216-A
Country	US
Kind code	A1
Filing date	Sep 18, 2015
Priority date	Sep 26, 2014
Publication date	Jul 6, 2017
Grant date	—

Abstract

Provided is a cocktail of factors for converting/reprogramming non-naïve pluripotent stem cells into TGFβ signaling-independent (TSI) naïve induced pluripotent stem cells (iPSCs). Also provided are methods for reprograming a non-naïve PSC into a TSI naïve iPSC by contacting the cell to be reprogrammed with effective amounts of compounds for a sufficient period of time to reprogram the cell into a TSI naïve iPSC.

First claim

1 . A cell culture media composition for extending cell potency of isolated pluripotent cells, the composition comprising chemical inducer of naive pluripotency (CINP) from each of the following groups
(1) a cytokine, (2) a glycogen synthase kinase (GSK) inhibitor, (3 an extracellular sign regulated kinase (ERK) 1/2 inhibitor (4) a c-Jun N-terminal kinase (JNK) inhibitor, (5) basic fibroblast growth factor (bFGF), and (6) a p38 mitogen-activated protein kinase (MAPK) inhibitor in amounts effective to reprogram of a non-naive cell, into a TGFP signaling independent (TSI) naive induced pluripotent stem cell (PSC).

2 . The composition of claim 1 , wherein the cytokine is selected from the group consisting of human inhibitory fact (LIF, “L”), interleukin (IL)-6, IL-11, IL-27, IL-31, leukemia inhibitory factor, oncostatin M, cardiotrophin-1, neuropoietin and cardiotrophin-like cytokine factor 1.

3 . The composition of claim 1 , wherein the GSK inhibitor is a GSK3 inhibitor.

4 . The composition of claim 1 , wherein the ERK) 1/2 inhibitor is selected from the group consisting of PD0325901 (N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide); PD198306 (N-(Cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2-methylphenyl)amino]-benzamide); SL 327 (α-[Amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile); and U0126 (1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene);
wherein the GSK inhibitor is selected from the group consisting of CHIR99021 [6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile]; BIO-acetoxime; GSK 3I inhibitor XV; SB-216763; CHIR 99021 trihydrochloride; GSK-3 Inhibitor IX [((2Z,3E)-6′-bromo-3-(hydroxyimino)-[2,3′-biindolinylidene]-2′-one]; GSK 3 IX [6-Bromoindirubin-3′-oxime]; GSK-313 Inhibitor XII [3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol]; GSK-3 Inhibitor XVI [6-(2-(4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino)ethyl-amino)-nicotinonitrile]; SB-415286 [3-[3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione]; and Bio [2′Z,3′E)-6-bromoindirubin-3′-oxime];
wherein the JNK inhibitor is selected from the group consisting of SP600125 (Anthra[1-9-cd]pyrazol-6(2H)-one); I 78D3 (4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one); CEP 1347 ((9S,10R,12R)-5-16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-l-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester); and SU 3327 (−[(5-Nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine); or
wherein the p38 MAPK inhibitor is selected from the group consisting of SB 203580 hydrochloride (4-[5-(4-Fluorophenyl)-2-[4-(methylsulphonyl)phenyl]-1H-imidazol-4-yl]pyridine hydrochloride); SB202190 (4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol); DBM 1285 dihydrochloride (N-Cyclopropyl-4-[4-(4-fluorophenyl)-2-(4-piperidinyl)-5-thiazolyl]-2-pyrimidinamine dihydrochloride); SB 239063 (trans-4-[4-(4-Fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol); SKF 86002 dihydrochloride (6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo[2,1-b]thiazole dihydrochloride).

5 - 7 . (canceled)

8 . The composition of claim 4 comprising CHIR99021; PD0325901; bFGF; SP600125; SB 203580 and SP600125.

9 . (canceled)

10 . The composition of claim 4 in a kit, wherein the small molecular weight compounds are present in relative amounts to put into cell culture media for differentiated cells to induce naive pluripotency.

11 . A method of producing TSI naive PSC comprising:
culturing a donor cells with the composition of claim 1 for a period of time effective to reprogram a non-naive PSC into a TSI naive PSC and optionally, isolating the TSI naïve PSC.

12 . The method of claim 11 , wherein the donor cells are selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, multipotent stem cells, cells of hematological origin, cells of embryonic origin, skin derived cells, fibroblasts, adipose cells, epithelial cells, endothelial cells, mesenchymal cells, parenchymal cells, neurological cells, and connective tissue cells.

13 . The method of claim 12 , wherein the donor cells are selected from the group consisting of mouse embryonic stem cells, human embryonic stem cells, and induced pluripotent stem cells.

14 . The method of claim 11 , wherein the donor cells are cultured for a period ranging from 4 to 14 days.

15 . (canceled)

16 . The method of claim 11 , wherein the TSI naive PSC are seeded as single cells, the method further comprising culturing the cells in cell culture medium comprising the composition of claim 1 .

17 . A population of isolated TSI naive PSC obtained by the method of claim 11 .

18 . (canceled)

19 . The population of cells of claim 17 , wherein expression of at least one marker selected from the group consisting of PRDM14, KLFS, ZFP42 (REX1), LIFR, TBX3, TRA-1-60, TRA-1-81, SSEA-4 and NANOG is upregulated when compared to untreated corresponding cells isolated from the same organism as the donor cells.

20 . (canceled)

21 . The population of cells of claim 17 , wherein expression of SSAEA-1 is down regulated when compared to untreated corresponding cells isolated from the corresponding organism as the donor cells.

22 . The population of cells of claim 17 wherein the cells maintain pluripotency following culture in the presence of a TGFβ receptor inhibitor for at least five days, as measured by fold change in the proportion of TRA-1-81-positive cells relative to controls in the presence of a TGFβ receptor inhibitor.

23 . The An isolated population of cells of claim 17 comprising at least 10%, 20% 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% TSI naive PSC.

24 . (canceled)

25 . The cell culture of claim 1 , further comprising isolated TSI naive PSC obtained by a method comprising culturing donor cells in a culture medium comprising a cytokine,
(2) a glycogen synthase kinase (GSK) inhibitor, (3 an extracellular sign regulated kinase (ERK) 1/2 inhibitor (4) a c-Jun N-terminal kinase (INK) inhibitor, (5) basic fibroblast growth factor (bFGF), and (6) a p38 mitogen-activated protein kinase (MAPK) inhibitor, wherein the culture medium effectively maintains the TSI naive PSC in an undifferentiated and naive pluripotent state for at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 passages, or the TSI naive PSC maintain a normal karyotype in culture after up to 8 months in culture, or both.

26 - 27 . (canceled)

28 . A method for producing an organ in a recipient non-human mammal having an abnormality associated with a lack of development of the target organ in a development stage, comprising: a) preparing TSI naive PSC derived from a donor mammal; b) transplanting the TSI naive PSC into a blastocyst stage fertilized egg of the recipient mammal; c) developing the fertilized egg in a womb of a non-human surrogate parent mammal to obtain a litter; and d) obtaining the target organ from the litter.

29 . The method of claim 28 , wherein the organ to be produced is selected from the group consisting of a pancreas, a kidney, a thymus, and a hair.

30 . The method of claim 28 the recipient mammal is a mouse selected fro

Assignees

• Hong Guan Ltd
• Univ Beijing
• Beijing Vitalstar Biotechnology Co Ltd

Inventors

• Deng Hongkui
• Fang Riguo
• Liu Kang
• Yang Weifeng

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A01K2267/025

  Animal producing cells or organs for transplantation · CPC title

• C12N2506/09

  from epidermal cells, from skin cells, from oral mucosa cells · CPC title

• C12N2501/20

  Cytokines; Chemokines · CPC title

• C12N2501/115

  Basic fibroblast growth factor (bFGF, FGF-2) · CPC title